The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...

Nearly all of the patients who responded to the a personalized mRNA pancreatic vaccine are still alive six years later.

The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca, while SynOx Therapeutics is planning to enter a market served by companie ...

BioNTech’s fair value estimate has been trimmed from $139.51 to $131.39, a modest cut of about 6% that reflects the latest model inputs. This shift comes as analysts reassess the story around ...

BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress. Intellia Therapeutics faces ...

While BioNTech's substantial cash reserve of 17.2 billion euros provides a near-term buffer, the company faces a costly transition. Research and development expenses are projected to climb to as much ...

Amid growing financial concerns and US vaccine hesitancy, the German company will close its mRNA site in Southeast Asia.

The company's shares recently gained nearly 10% in a week, closing at 87.00 EUR, as it presented compelling evidence for its strategic shift into oncology. The most striking data came from a Phase 2 ...